December 8, 2025BloodOpen Access

Incidence of arterial thromboembolism in patients with myeloproliferative neoplasms treated with anticoagulation for venous thromboembolism

View Full Paper

Ask AI

Bookmark

Authors

ACAntonia ChanBeth Israel Deaconess Medical Center ALAvi LeaderMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Retrospective analysis reveals a 6.4% incidence of arterial thromboembolism in myeloproliferative neoplasm patients on anticoagulation for venous thromboembolism, implying a crucial need for risk-redu

Key Points

To determine the incidence of arterial thromboembolism in patients with myeloproliferative neoplasms receiving anticoagulation for venous thromboembolism.
Conducted a retrospective study at two major cancer centers (MSKCC and BIDMC) from 2000 to 2025.
Included patients with myeloproliferative neoplasms and a history of venous thromboembolism.
Documented anticoagulation therapy types and stratified outcomes based on concomitant antiplatelet therapy.
Total of 105 patients included, median age 71, with 6.4% cumulative incidence of arterial thromboembolism at 3 years.
Major bleeding incidence was 1.9% at 6 months, lower than arterial thromboembolism incidence.
Ischemic stroke was the most frequent arterial thromboembolism event, with a higher risk seen in patients receiving antiplatelet therapy.

Cite This Study

Chan et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d493 https://doi.org/10.1182/blood-2025-3138

View Full Paper

Ask AI

Bookmark

Incidence of arterial thromboembolism in patients with myeloproliferative neoplasms treated with anticoagulation for venous thromboembolism

Discussion

Member takes

Implication

Key Points

Cite This Study

Incidence of arterial thromboembolism in patients with myeloproliferative neoplasms treated with anticoagulation for venous thromboembolism

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider